Azelnidipine

Azelnidipine

Azelnidipine

Antihypertensive drug of the calcium channel blocker class

Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)[1] In 2020.

Quick Facts Clinical data, Trade names ...

References

  1. [1]
    Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (September 1989). "Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker". Jpn. J. Pharmacol. 51 (1): 57–64. doi:10.1254/jjp.51.57. PMID 2810942.Scholar search Archived 2021-09-30 at the Wayback Machine
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Azelnidipine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.